Small molecules focused on GPCR targets for oncology indications

Teon Therapeutics is focused on developing innovative cancer therapies that aim to restore anti-tumor immunity through the targeting of unexploited metabolic signaling pathways. The company emphasizes the importance of G-protein-coupled receptors (GPCRs), which play a crucial role in various cellular processes related to tumor formation and progression. By leveraging their expertise in GPCR signaling and small molecule design, Teon is advancing a clinical-stage pipeline of therapies that include first- and best-in-class candidates. These therapies are designed to reverse immune cell suppression and inhibit tumor growth, ultimately providing better outcomes for patients with difficult-to-treat cancers.

Among Teon's notable candidates are TT-702, an adenosine A2B receptor antagonist, and TT-816, a cannabinoid CB2 receptor antagonist. TT-702 is currently in clinical trials for metastatic castration-resistant prostate cancer and triple-negative breast cancer, working to expose tumors to the immune system and prevent their proliferation. Meanwhile, TT-816 is being evaluated for its potential to enhance immune responses against various solid tumors. By targeting these specific receptors, Teon aims to address significant unmet needs in cancer care, offering patients more effective and convenient treatment options that allow them to spend more time with their loved ones.

United States

Teon is a clinical-stage company targeting metabolic signaling pathways and pioneering the development of GPCR immunotherapies in difficult-to-treat cancers.

Cancer

Digestive System Diseases

Kidney Diseases

Skin Diseases

Urogenital Diseases

Teon Therapeutics

Non-small cell lung carcinoma

Ovarian cancer

Renal cell carcinoma

TT-816

Small Molecule Pharmaceuticals

Castration-resistant prostate cancer

Colorectal cancer

Triple-negative breast cancer

TT-702

California - North

California

Marijuana/Cannabinoid-Derived Drugs

Contract Manufacturing

Therapeutic

Teon Therapeutics

Company Details